Marketing
-
Pfizer, BioNTech win EU vaccine approval as UK grapples with new coronavirus variant
In a press conference on the authorization, BioNTech CEO Ugur Sahin expressed confidence the vaccine would protect against the emerging virus variant in the U.K.
By Ned Pagliarulo • Dec. 22, 2020 -
Sponsored by IQVIA
The role of optimized omnichannel marketing in a challenging environment
How can pharma marketers overcome today's cost-constrained, competitive environment?
-
Hospitals start coronavirus vaccinations in sweeping, nationwide effort
A New York nurse was among the first to get the shot after FDA authorization last week. Many other health systems are either preparing to receive supplies or are already beginning immunizations.
By Samantha Liss • Dec. 14, 2020 -
UK drug regulator is first to clear Pfizer, BioNTech's coronavirus vaccine
The approval is a notable milestone in the historic pursuit of a protective shot for COVID-19. The two drugmakers plan to ship the first doses within days.
By Jonathan Gardner • Dec. 02, 2020 -
CDC panel recommends giving first coronavirus vaccines to healthcare workers, nursing home residents
Advisers on the CDC panel cited risk and disease burden as reasons for setting their priority list for the first vaccine doses to become available, supply of which will be extremely limited.
By Jonathan Gardner • Dec. 01, 2020 -
Deep Dive
Hospitals scramble to get ready for coronavirus vaccines
Facilities are preparing ultra-cold storage capabilities and reviewing security plans as they brace for their role in distributing potentially multiple shots.
By Shannon Muchmore • Nov. 19, 2020 -
As US cases surge, FDA clears first fully at-home COVID-19 test
The prescription test from Lucira Health can deliver results within 30 minutes, and could help boost U.S. testing capacity. Some experts, however, called for more guidance on proper use.
By Greg Slabodkin • Nov. 18, 2020 -
Copycat to top-selling eye drug takes a step toward market
The FDA is reviewing Samsung Bioepis and Biogen's biosimilar of Lucentis. If approved, it would be the first biosimilar for an eye disease drug.
By Kristin Jensen • Nov. 18, 2020 -
Sponsored by IQVIA
Finding the right mix: Digital transformation offers opportunities for improved HCP engagement
Field teams and HCPs alike are learning how digital, data-driven approaches can best support safe, productive engagement.
-
Trump administration to require insurers cover coronavirus vaccines
Late-stage vaccine results are expected soon from Pfizer and Moderna, putting pressure on the Trump administration to put in motion plans for what's likely to be a complex and challenging distribution process.
By Shannon Muchmore • Oct. 29, 2020 -
EQRx builds cancer drug pipeline as plans to challenge big pharma take shape
The startup, which aims to develop lower-cost alternatives to branded medicines, has licensed two drugs from CStone Pharmaceuticals in a deal that could signal a coming price war in cancer immunotherapy.
By Kristin Jensen • Oct. 27, 2020 -
Facing vaccine doubts, US grapples with building confidence in coronavirus shots
The CDC, for example, doesn't support vaccine mandates for healthcare workers or essential employees, an agency official told experts convened by the FDA last week.
By Jonathan Gardner • Oct. 22, 2020 -
Purdue, reaching $8B settlement with US, pleads guilty to charges over opioid sales
Under a deal reached with the Department of Justice, Purdue faces fines and a forfeiture worth more than $5 billion — the largest penalties ever for a drug company.
By Jacob Bell • Oct. 21, 2020 -
Sponsored by Veeva Crossix
Doctors are consumers too! How DTC media impacts HCPs
The findings have implications for how pharma teams should think about their DTC and HCP efforts — they are no longer two separate marketing channels.
-
Nestlé makes newly acquired Aimmune a stand-alone unit, appoints new CEO
Andrew Oxtoby, formerly chief commercial officer at the peanut allergy drugmaker, will take over as head of the new Nestlé business.
By Kristin Jensen • Oct. 14, 2020 -
FDA moves to pull preterm birth drug from market
AMAG Pharma, the maker of Makena, said the company disagreed with the FDA's proposal and plans to evaluate its options following a failed study.
By Kristin Jensen • Oct. 07, 2020 -
Sponsored by IQVIA
Achieving success in pharma marketing: The need for a personalized, omnichannel approach
Personalized, insight-driven omnichannel marketing has never been more beneficial or important.
-
After setback in the US, Galapagos' main drug finds success elsewhere
A month after the FDA surprisingly rejected the rheumatoid arthritis drug, called filgotinib, it's been cleared by regulators in Europe and Japan.
By Jacob Bell • Sept. 28, 2020 -
Health insurer sues Indivior over 'profit protection scheme'
Centene aims to recoup money it paid for Indivior's Suboxone product, alleging the drugmaker devised a plan to box out generic competitors.
By Samantha Liss • UPDATED: Sept. 23, 2020 at 11:47 a.m. -
Cigna rebrands health services division, including Express Scripts, as Evernorth
The change, which has been in the works since before the pandemic, is the next step in integrating the companies' business since their merger in 2018.
By Rebecca Pifer • Sept. 16, 2020 -
Hospitals urge HHS to step in on 340B fight with drugmakers
The dispute stems from drugmakers deciding to stop giving 340B discounts to contract pharmacies, which many hospitals use.
By Shannon Muchmore • Sept. 09, 2020 -
Thermo Fisher deal for Qiagen falls apart after companies fail to secure investor backing
Thermo Fisher had raised its bid for Qiagen to about $12.5 billion, but less than half of the company's shares were tendered by the offer's expiration Monday.
By Nick Paul Taylor , Maria Rachal , Greg Slabodkin • UPDATED: Aug. 13, 2020 at 11:39 a.m. -
Bristol Myers pledges to spend $300M on addressing racial, health disparities
The drugmaker aims to double Black and Latinx representation in its executive ranks, among other commitments.
By Kristin Jensen • Aug. 12, 2020 -
First liquid biopsy test that uses advanced gene sequencing approved by FDA
The test, developed by Guardant Health, combines next-generation sequencing with a cancer blood test.
By Susan Kelly • Aug. 10, 2020 -
Amarin decides to go it alone in Europe, as uncertainty clouds heart drug's US future
Chief executive John Thero said the company decided against "multiple proposals" for sales partnerships on Vascepa in Europe. Doing so, however, keeps the pressure on Amarin to deliver.
By Ben Fidler • Aug. 04, 2020